No abstract

No abstract

In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt ® ), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt ® -treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (−41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that −41.03%, to −38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and 64.12% after the fifth month.

HIV/AIDS is an immune deficiency disease, caused by an RNA virus (positively charged pathogen). It is still being regarded as mysteriously incurable but in Nigeria many patients have been cured (they became HIV-antibody and antigen negative) by exploiting electrostatic attraction between pathogens and opposite electrical charges that are on Nanoparticles of Medicinal synthetic Aluminum-magnesium silicate (MSAMS) and by using antioxidants to relieve oxidative stress. To confirm the cure, as permanent, a patient (adult male) whose CD4 count increased (P < 0.05) from 685 to 820 while his viral load became undetectable (<20) and he became HIV-negative (antibody and antigen) following the treatment, was tested, every month, post treatment, for HIV-antibody. He has remained HIV-negative for 10 months without being on any antiretroviral medicine (ARV). Longest window period (period HIV-infected person may test antibody-negative) is only 6 months. These results confirm that treatment with the MSAMS and antioxidants normalizes immunity and terminates HIV-infections.

Background: Rheumatoid arthritis is a chronic autoimmune disease that causes socio-economic, psychological and sexual problems. It imposes limitations on sexual relationships and these issues are still taboo in African society. Objective: The objective is to assess the impact of rheumatoid arthritis (RA) on women's sexuality at the Ignace Deen National Hospital. Patients and Methods: This was an analytic case-control study of 8 months (from April 6, 2020 to December 11, 2020). All patients followed for rheumatoid arthritis diagnosed according to 2010 ACR/EULAR criteria for RA had been included. Results: One hundred and five women (52 RA patients and 53 controls) were collected. The two groups were comparable in terms of demographic characteristics. Sexual dysfunction was found in 69.2% of cases versus 35.8% of controls. Women with RA had poorer sexual functioning in the categories of desire, arousal, lubrication, orgasm, satisfaction, and pain of the FSFI score compared to healthy women (p = 0.01; p = 0.7; p = 0.3; p = 0.8; p = 0.1; and p = 0.3 respectively). Patients were 4 times more likely to have sexual dysfunction than healthy individuals and this result was statistically significant with a p-value less than 0.05. Conclusion: Sexual dysfunction was noted in a large number of RA patients surveyed at the rheumatology department of the Ignace Deen national hospital. A larger study is needed to better assess this issue and seek management solutions.